Bioluminescent assays for ADMET

Author： Cali James J   Niles Andrew   Valley Michael P   O'Brien Martha A   Riss Terry L   Shultz John  

Publisher： Informa Healthcare

ISSN： 1742-5255

Source： Expert Opinion on Drug Metabolism and Toxicology, Vol.4, Iss.1, 2008-01, pp. : 103-120

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

ADMET considerations for phosphodiesterase-5 inhibitors

By Rezvanfar Mohammad Amin   Rahimi Hamid Reza   Abdollahi Mohammad  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 8, Iss. 10, 2012-10 ,pp. : 1231-1245

Informa Healthcare

Access to resources Recommend Favorite

Discovery and ADMET: Where Are We Now

By  

Current Topics in Medicinal Chemistry, Vol. 11, Iss. 4, 2011-02 ,pp. : 467-481

Bentham Science Publishers

Access to resources Recommend Favorite

ADMET considerations for restless leg syndrome drug treatments

By de Biase Stefano   Merlino Giovanni   Lorenzut Simone   Valente Mariarosaria   Gigli Gian Luigi  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 8, Iss. 10, 2012-10 ,pp. : 1247-1261

Informa Healthcare

Access to resources Recommend Favorite

Designing PEGylated therapeutic molecules: advantages in ADMET properties

By Hamidi Mehrdad   Rafiei Pedram   Azadi Amir  

Expert Opinion on Drug Discovery, Vol. 3, Iss. 11, 2008-11 ,pp. : 1293-1307

Informa Healthcare

Access to resources Recommend Favorite

Positioning ADMET in silico tools in drug discovery

By Modi S.  

Drug Discovery Today, Vol. 9, Iss. 1, 2004-01 ,pp. : 14-15

Elsevier

Access to resources Recommend Favorite